January 2016 Volume 12, Issue 1
Volume 12, Issue 1 | January 2016
January 2016
In this Issue
Special Reports
Special Report on regenerative medicine: Outside, looking in
Regenerative medicine turns its focus on the eyeQ&A
Q&A: RNA therapies aimed at solving cardiometabolic and lipid disorders
DDNews conducts a Q&A with Paula Soteropoulos of Akcea Therapeutics on transforming the landscape of cardiometabolic lipid disordersEditor's Focus
Still no silver bullet, but progress continues against cancer
Between the FDA picking up the pace and researchers devoting ever more knowledge and resources, we may start to gain ground in the oncology raceResearch & Development
A gut-check for answers
New study reveals why the gastrointestinal microbiota affects diseaseCold facts
Oregon team refines cryopreservation techniqueOpening access to ‘vital’ cell lines
Michael J. Fox Foundation looks ‘back to the future’ toward a speedy cure for Parkinson’s diseaseDealing across the coasts
N.J.-based Worthington and San Diego-based Cytori ink distribution deal for GMP enzymeAdaptimmune and Universal Cells announce collaboration to develop allogeneic T Cell Therapies
Adaptimmune and Universal Cells announce collaboration to develop allogeneic T Cell TherapiesDiscovery
Novel drivers of clinical outcomes uncovered in multiple myeloma
Multiple Myeloma Research Foundation and GNS Healthcare present data from longitudinal studyCracking the code of CFTR
TSRI scientists find crucial disease-specific protein interactions in cystic fibrosisAptose expands oncology pipeline through partnerships
Canadian company links up with Moffitt and Laxai Avanti Life SciencesTransformative therapy
Collaboration focuses on molecular target for unmet medical needUniquely human gene variants protect older adults from cognitive decline
UC San Diego School of Medicine researchers detail gene variants that convey protection against neurodegenerative and cardiovascular diseasesBusiness & Government Policy
FDA beats the averages on approvals
FDA’s Center for Drug Evaluation and Research approves 45 novel new therapies in 2015Hyped for HBV
Johnson & Johnson acquires Novira Therapeutics and HBV portfolio in year-end dealAstraZeneca makes $575M deal for Takeda's respiratory business
Deal, which is one several at year’s end, includes expansion of rights to roflumilast, the only approved oral PDE4 inhibitor for COPDOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsDiagnostics
Never leave a cell behind
Epic Sciences brings its ‘no cell left behind’ technology to partner with Penn Medicine Abramson Cancer CenterPrecision medicine unleashed
Whole-exome sequencing test reveals untapped therapeutic optionsVectra DA making waves in RA
Crescendo shares data highlighting the test’s ability to better depict disease activityContract Services
Two for tissues
ReproCELL acquires life-sciences CRO BioptaA cancer antibody with more punch
Zymeworks contracts ProBioGen for bispecific GlymaxX antibody cell line development to enhance ADCC potency of antibodyVetter establishes Japan office to bolster Asian inroads
Company’s second office in the region will strengthen customer relations and help develop new business among emerging and established Japanese companiesPreclinical
Oncology therapeutics on the move
Sunesis is advancing its BTK and PDK1 inhibitor programs to aid cancer patientsTwice as nice
OncoMed’s preclinical comparison study shows improved antitumore, immune responses for bispecific antibodyNanoBio chlamydia vaccine prevents PID in mice
Nanoemulsion adjuvanted vaccines demonstrate positive preclinical results in genital herpes, HIV and chlamydiaClinical Trials
Relief in sight with FDX104?
Phase 2 data is positive for Foamix’s acneiform rash treatmentCluePoints not ‘clueless’ when it comes to RBM solutions
Company initiates collaboration with Widler & Schiemann on risk management in trialsInitial data for IMO-8400
Idera Pharmaceuticals reports positive data from ongoing Phase 1/2 clinical trial of toll-like receptor in patients with Waldenström’s macroglobulinemiaSurvey reveals majority of life-sciences companies lack automated processes
Industry leaders are adopting ‘best of breed’ applications in eClinical stack to speed clinical trialsCommentary
Out of order: Avoiding extremes
We must strive to avoid getting swept up in hype and then forget or minimize existing limitations and challenges as we try to turn exciting discoveries into life-altering products and servicesA very busy 2016? The intersection of M&As and personalized medicine
M&As are going strong and personalized medicine is a growing force; the two are not always intertwined, but in 2016 things may shift toward them being more so than they have been
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The crucial role of sample preparation in biotherapy manufacturing
Discover how better sample preparation can unlock improved assay accuracy and analytical results.
Discovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Accelerating RNA therapeutic testing with liver microphysiological platforms
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
